Systems thinking in medicine and new drug discovery.: Volume two /
This second book in a two-volume set tells how the healthcare community is working with patients and their caregivers to help improve health using P4 medicine, proper nutrition and a healthy lifestyle. The healthcare community is finding ways to predict one's susceptibility to diseases, so they...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Newcastle upon Tyne :
Cambridge Scholars Publishing,
2018.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | This second book in a two-volume set tells how the healthcare community is working with patients and their caregivers to help improve health using P4 medicine, proper nutrition and a healthy lifestyle. The healthcare community is finding ways to predict one's susceptibility to diseases, so they can be prevented from occurring, when possible. When diseases do emerge, it is developing personalized therapies and ways for patients to participate in their own healthcare. At the same time, systems thinking dispels many misconceptions, such as 'natural' foods and 'superfoods'. In fact, the only true. |
| Beschreibung: | 1 online resource (xiv, 333 pages) : illustrations |
| Bibliographie: | Includes bibliographical references and index. |
| ISBN: | 9781527523777 1527523772 |
Internformat
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-on1081038825 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 190107s2018 enka ob 001 0 eng d | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d N$T |d YDX |d EBLCP |d UKMGB |d UKAHL |d OCLCQ |d ELBRO |d OCLCO |d OCLCQ |d OCLCO |d K6U |d OCLCQ |d OCLCO |d OCLCL | ||
| 015 | |a GBB912898 |2 bnb | ||
| 016 | 7 | |a 019205923 |2 Uk | |
| 020 | |a 9781527523777 |q (electronic bk.) | ||
| 020 | |a 1527523772 |q (electronic bk.) | ||
| 020 | |z 1527506126 | ||
| 020 | |z 9781527506121 | ||
| 035 | |a (OCoLC)1081038825 | ||
| 037 | |a 9781527523777 |b Cambridge Scholars Publishing | ||
| 050 | 4 | |a RM301.25 | |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 082 | 7 | |a 615.1/9 |2 23 | |
| 049 | |a MAIN | ||
| 100 | 1 | |a Smith, Robert E., |d 1951- |e author. |1 https://id.oclc.org/worldcat/entity/E39PCjJg6KytjbBhmWFvdmHh6q |0 http://id.loc.gov/authorities/names/n86012617 | |
| 245 | 1 | 0 | |a Systems thinking in medicine and new drug discovery. |n Volume two / |c by Robert E. Smith. |
| 264 | 1 | |a Newcastle upon Tyne : |b Cambridge Scholars Publishing, |c 2018. | |
| 300 | |a 1 online resource (xiv, 333 pages) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 504 | |a Includes bibliographical references and index. | ||
| 588 | 0 | |a Online resource; title from PDF title page (EBSCO, viewed January 8, 2019). | |
| 505 | 0 | |a Intro; Contents; Preface; Chapter One; 1.1 P4 medicine: predictive, preventive, personalized and participatory; 1.2 Systems primary care medicine; 1.3 Causality in P4SM; 1.4 Explanation, prediction and control in P4 me; 1.5 What P4 medicine does; 1.6 Examples of P4 medicine; 1.7 Important collaborations in P4 medicine; 1.8 P4 and evidence based medicine; 1.9 The Advancing Regulatory Science Initiative; 1.10 The voices of the people; 1.11 Limitations of P4 medicine; 1.12 Metabolomics; 1.12.1 Introduction; 1.12.2 Comparison of LC-MS and GC-MS; 1.12.3 NMR in metabolomics | |
| 505 | 8 | |a 1.12.4 Receiver operator characteristic (ROC) curves1.12.5 Acute kidney injury (AKI) metabolomics; 1.12.6 Chronic kidney disease (CKD) me; 1.12.7 Metabolomics of acute kidney injury; 1.12.8 Metabolomics of neonatal, pediatric and childhood kidney diseases; 1.12.9 Metabolomics of kidney cancer; 1.12.10 Proteomics; 1.13 Targeted radiation therapy; 1.14 Precision systems medicine that targets cancer stem cel; 1.15 Cancer prevention; 1.16 Systems medicine; References; Chapter Two; 2.1 Previous misconceptions caused by reductionist thinking; 2.2 Chemistry of free radicals and RONS | |
| 505 | 8 | |a 2.3 How antioxidants really work2.3.1 Poorly liganded iron and the Fenton reaction; 2.3.2 The Nrf2/ARE system; 2.4 The role of the Keap1-Nrf2-ARE signaling system in preventing cardiovascular diseases; 2.5 Role of the Nrf2/ARE antioxidant system in cancer and neurodegenerative diseases; 2.6 Smoldering inflammation; 2.7 The complement system and toll-like receptors in health and disease; References; Chapter Three; 3.1 Nutrition; 3.1.1 Fats; 3.1.2 Protein; 3.1.3 Carbohydrates; 3.1.4 Vitamins and; 3.1.5 Mother's milk -- the only true superfood; 3.2 Role of Lifestyle; References; Chapter Four | |
| 505 | 8 | |a 4.1 Introduction4.2 Epigenetic gene regulation; 4.3 Global climate change; References; Appendix; A1 Introduction; A2 The Nervous System; A2.1 Introduction; A2.2 Cells in the nervous system; A2.3 Regions of the brain; A2.4 Neurotransmitters, neurohormones and neuromodulators; A2.5 Small molecule neuroactive NO and CO; A3 The Endocrine System; A4 The Immune System; References; Abbreviations and Acronyms Used; Index | |
| 520 | |a This second book in a two-volume set tells how the healthcare community is working with patients and their caregivers to help improve health using P4 medicine, proper nutrition and a healthy lifestyle. The healthcare community is finding ways to predict one's susceptibility to diseases, so they can be prevented from occurring, when possible. When diseases do emerge, it is developing personalized therapies and ways for patients to participate in their own healthcare. At the same time, systems thinking dispels many misconceptions, such as 'natural' foods and 'superfoods'. In fact, the only true. | ||
| 650 | 0 | |a Drug development. |0 http://id.loc.gov/authorities/subjects/sh97007921 | |
| 650 | 0 | |a Pharmaceutical chemistry. |0 http://id.loc.gov/authorities/subjects/sh85023026 | |
| 650 | 0 | |a Integrative medicine. |0 http://id.loc.gov/authorities/subjects/sh2003001256 | |
| 650 | 0 | |a Human biology. |0 http://id.loc.gov/authorities/subjects/sh85062843 | |
| 650 | 2 | |a Chemistry, Pharmaceutical |0 https://id.nlm.nih.gov/mesh/D002626 | |
| 650 | 6 | |a Médicaments |x Développement. | |
| 650 | 6 | |a Chimie pharmaceutique. | |
| 650 | 6 | |a Médecine intégrative. | |
| 650 | 6 | |a Biologie humaine. | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a Drug development |2 fast | |
| 650 | 7 | |a Human biology |2 fast | |
| 650 | 7 | |a Integrative medicine |2 fast | |
| 650 | 7 | |a Pharmaceutical chemistry |2 fast | |
| 758 | |i has work: |a Volume 2 Systems thinking in medicine and new drug discovery [...] (Text) |1 https://id.oclc.org/worldcat/entity/E39PCH4pMpM4bBV9fDtcf9Yr7b |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1993859 |3 Volltext |
| 938 | |a Askews and Holts Library Services |b ASKH |n AH35847252 | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL5628828 | ||
| 938 | |a EBSCOhost |b EBSC |n 1993859 | ||
| 938 | |a eLibro |b ELBO |n ELB119486 | ||
| 938 | |a YBP Library Services |b YANK |n 15956206 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-on1081038825 |
|---|---|
| _version_ | 1816882481583882240 |
| adam_text | |
| any_adam_object | |
| author | Smith, Robert E., 1951- |
| author_GND | http://id.loc.gov/authorities/names/n86012617 |
| author_facet | Smith, Robert E., 1951- |
| author_role | aut |
| author_sort | Smith, Robert E., 1951- |
| author_variant | r e s re res |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RM301 |
| callnumber-raw | RM301.25 |
| callnumber-search | RM301.25 |
| callnumber-sort | RM 3301.25 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| collection | ZDB-4-EBA |
| contents | Intro; Contents; Preface; Chapter One; 1.1 P4 medicine: predictive, preventive, personalized and participatory; 1.2 Systems primary care medicine; 1.3 Causality in P4SM; 1.4 Explanation, prediction and control in P4 me; 1.5 What P4 medicine does; 1.6 Examples of P4 medicine; 1.7 Important collaborations in P4 medicine; 1.8 P4 and evidence based medicine; 1.9 The Advancing Regulatory Science Initiative; 1.10 The voices of the people; 1.11 Limitations of P4 medicine; 1.12 Metabolomics; 1.12.1 Introduction; 1.12.2 Comparison of LC-MS and GC-MS; 1.12.3 NMR in metabolomics 1.12.4 Receiver operator characteristic (ROC) curves1.12.5 Acute kidney injury (AKI) metabolomics; 1.12.6 Chronic kidney disease (CKD) me; 1.12.7 Metabolomics of acute kidney injury; 1.12.8 Metabolomics of neonatal, pediatric and childhood kidney diseases; 1.12.9 Metabolomics of kidney cancer; 1.12.10 Proteomics; 1.13 Targeted radiation therapy; 1.14 Precision systems medicine that targets cancer stem cel; 1.15 Cancer prevention; 1.16 Systems medicine; References; Chapter Two; 2.1 Previous misconceptions caused by reductionist thinking; 2.2 Chemistry of free radicals and RONS 2.3 How antioxidants really work2.3.1 Poorly liganded iron and the Fenton reaction; 2.3.2 The Nrf2/ARE system; 2.4 The role of the Keap1-Nrf2-ARE signaling system in preventing cardiovascular diseases; 2.5 Role of the Nrf2/ARE antioxidant system in cancer and neurodegenerative diseases; 2.6 Smoldering inflammation; 2.7 The complement system and toll-like receptors in health and disease; References; Chapter Three; 3.1 Nutrition; 3.1.1 Fats; 3.1.2 Protein; 3.1.3 Carbohydrates; 3.1.4 Vitamins and; 3.1.5 Mother's milk -- the only true superfood; 3.2 Role of Lifestyle; References; Chapter Four 4.1 Introduction4.2 Epigenetic gene regulation; 4.3 Global climate change; References; Appendix; A1 Introduction; A2 The Nervous System; A2.1 Introduction; A2.2 Cells in the nervous system; A2.3 Regions of the brain; A2.4 Neurotransmitters, neurohormones and neuromodulators; A2.5 Small molecule neuroactive NO and CO; A3 The Endocrine System; A4 The Immune System; References; Abbreviations and Acronyms Used; Index |
| ctrlnum | (OCoLC)1081038825 |
| dewey-full | 615.1/9 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.1/9 |
| dewey-search | 615.1/9 |
| dewey-sort | 3615.1 19 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05700cam a2200685 i 4500</leader><controlfield tag="001">ZDB-4-EBA-on1081038825</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr cnu---unuuu</controlfield><controlfield tag="008">190107s2018 enka ob 001 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">N$T</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="e">pn</subfield><subfield code="c">N$T</subfield><subfield code="d">N$T</subfield><subfield code="d">YDX</subfield><subfield code="d">EBLCP</subfield><subfield code="d">UKMGB</subfield><subfield code="d">UKAHL</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">ELBRO</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">K6U</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield></datafield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">GBB912898</subfield><subfield code="2">bnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">019205923</subfield><subfield code="2">Uk</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781527523777</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1527523772</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">1527506126</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781527506121</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1081038825</subfield></datafield><datafield tag="037" ind1=" " ind2=" "><subfield code="a">9781527523777</subfield><subfield code="b">Cambridge Scholars Publishing</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RM301.25</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">071000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">615.1/9</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Smith, Robert E.,</subfield><subfield code="d">1951-</subfield><subfield code="e">author.</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCjJg6KytjbBhmWFvdmHh6q</subfield><subfield code="0">http://id.loc.gov/authorities/names/n86012617</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Systems thinking in medicine and new drug discovery.</subfield><subfield code="n">Volume two /</subfield><subfield code="c">by Robert E. Smith.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Newcastle upon Tyne :</subfield><subfield code="b">Cambridge Scholars Publishing,</subfield><subfield code="c">2018.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xiv, 333 pages) :</subfield><subfield code="b">illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Online resource; title from PDF title page (EBSCO, viewed January 8, 2019).</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Intro; Contents; Preface; Chapter One; 1.1 P4 medicine: predictive, preventive, personalized and participatory; 1.2 Systems primary care medicine; 1.3 Causality in P4SM; 1.4 Explanation, prediction and control in P4 me; 1.5 What P4 medicine does; 1.6 Examples of P4 medicine; 1.7 Important collaborations in P4 medicine; 1.8 P4 and evidence based medicine; 1.9 The Advancing Regulatory Science Initiative; 1.10 The voices of the people; 1.11 Limitations of P4 medicine; 1.12 Metabolomics; 1.12.1 Introduction; 1.12.2 Comparison of LC-MS and GC-MS; 1.12.3 NMR in metabolomics</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">1.12.4 Receiver operator characteristic (ROC) curves1.12.5 Acute kidney injury (AKI) metabolomics; 1.12.6 Chronic kidney disease (CKD) me; 1.12.7 Metabolomics of acute kidney injury; 1.12.8 Metabolomics of neonatal, pediatric and childhood kidney diseases; 1.12.9 Metabolomics of kidney cancer; 1.12.10 Proteomics; 1.13 Targeted radiation therapy; 1.14 Precision systems medicine that targets cancer stem cel; 1.15 Cancer prevention; 1.16 Systems medicine; References; Chapter Two; 2.1 Previous misconceptions caused by reductionist thinking; 2.2 Chemistry of free radicals and RONS</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">2.3 How antioxidants really work2.3.1 Poorly liganded iron and the Fenton reaction; 2.3.2 The Nrf2/ARE system; 2.4 The role of the Keap1-Nrf2-ARE signaling system in preventing cardiovascular diseases; 2.5 Role of the Nrf2/ARE antioxidant system in cancer and neurodegenerative diseases; 2.6 Smoldering inflammation; 2.7 The complement system and toll-like receptors in health and disease; References; Chapter Three; 3.1 Nutrition; 3.1.1 Fats; 3.1.2 Protein; 3.1.3 Carbohydrates; 3.1.4 Vitamins and; 3.1.5 Mother's milk -- the only true superfood; 3.2 Role of Lifestyle; References; Chapter Four</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">4.1 Introduction4.2 Epigenetic gene regulation; 4.3 Global climate change; References; Appendix; A1 Introduction; A2 The Nervous System; A2.1 Introduction; A2.2 Cells in the nervous system; A2.3 Regions of the brain; A2.4 Neurotransmitters, neurohormones and neuromodulators; A2.5 Small molecule neuroactive NO and CO; A3 The Endocrine System; A4 The Immune System; References; Abbreviations and Acronyms Used; Index</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This second book in a two-volume set tells how the healthcare community is working with patients and their caregivers to help improve health using P4 medicine, proper nutrition and a healthy lifestyle. The healthcare community is finding ways to predict one's susceptibility to diseases, so they can be prevented from occurring, when possible. When diseases do emerge, it is developing personalized therapies and ways for patients to participate in their own healthcare. At the same time, systems thinking dispels many misconceptions, such as 'natural' foods and 'superfoods'. In fact, the only true.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drug development.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh97007921</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmaceutical chemistry.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85023026</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Integrative medicine.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh2003001256</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Human biology.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85062843</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Chemistry, Pharmaceutical</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D002626</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Médicaments</subfield><subfield code="x">Développement.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Chimie pharmaceutique.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Médecine intégrative.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Biologie humaine.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Pharmacology.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug development</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Human biology</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Integrative medicine</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical chemistry</subfield><subfield code="2">fast</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">Volume 2 Systems thinking in medicine and new drug discovery [...] (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCH4pMpM4bBV9fDtcf9Yr7b</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1993859</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Askews and Holts Library Services</subfield><subfield code="b">ASKH</subfield><subfield code="n">AH35847252</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL5628828</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">1993859</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">eLibro</subfield><subfield code="b">ELBO</subfield><subfield code="n">ELB119486</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">15956206</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-on1081038825 |
| illustrated | Illustrated |
| indexdate | 2024-11-27T13:29:18Z |
| institution | BVB |
| isbn | 9781527523777 1527523772 |
| language | English |
| oclc_num | 1081038825 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource (xiv, 333 pages) : illustrations |
| psigel | ZDB-4-EBA |
| publishDate | 2018 |
| publishDateSearch | 2018 |
| publishDateSort | 2018 |
| publisher | Cambridge Scholars Publishing, |
| record_format | marc |
| spelling | Smith, Robert E., 1951- author. https://id.oclc.org/worldcat/entity/E39PCjJg6KytjbBhmWFvdmHh6q http://id.loc.gov/authorities/names/n86012617 Systems thinking in medicine and new drug discovery. Volume two / by Robert E. Smith. Newcastle upon Tyne : Cambridge Scholars Publishing, 2018. 1 online resource (xiv, 333 pages) : illustrations text txt rdacontent computer c rdamedia online resource cr rdacarrier Includes bibliographical references and index. Online resource; title from PDF title page (EBSCO, viewed January 8, 2019). Intro; Contents; Preface; Chapter One; 1.1 P4 medicine: predictive, preventive, personalized and participatory; 1.2 Systems primary care medicine; 1.3 Causality in P4SM; 1.4 Explanation, prediction and control in P4 me; 1.5 What P4 medicine does; 1.6 Examples of P4 medicine; 1.7 Important collaborations in P4 medicine; 1.8 P4 and evidence based medicine; 1.9 The Advancing Regulatory Science Initiative; 1.10 The voices of the people; 1.11 Limitations of P4 medicine; 1.12 Metabolomics; 1.12.1 Introduction; 1.12.2 Comparison of LC-MS and GC-MS; 1.12.3 NMR in metabolomics 1.12.4 Receiver operator characteristic (ROC) curves1.12.5 Acute kidney injury (AKI) metabolomics; 1.12.6 Chronic kidney disease (CKD) me; 1.12.7 Metabolomics of acute kidney injury; 1.12.8 Metabolomics of neonatal, pediatric and childhood kidney diseases; 1.12.9 Metabolomics of kidney cancer; 1.12.10 Proteomics; 1.13 Targeted radiation therapy; 1.14 Precision systems medicine that targets cancer stem cel; 1.15 Cancer prevention; 1.16 Systems medicine; References; Chapter Two; 2.1 Previous misconceptions caused by reductionist thinking; 2.2 Chemistry of free radicals and RONS 2.3 How antioxidants really work2.3.1 Poorly liganded iron and the Fenton reaction; 2.3.2 The Nrf2/ARE system; 2.4 The role of the Keap1-Nrf2-ARE signaling system in preventing cardiovascular diseases; 2.5 Role of the Nrf2/ARE antioxidant system in cancer and neurodegenerative diseases; 2.6 Smoldering inflammation; 2.7 The complement system and toll-like receptors in health and disease; References; Chapter Three; 3.1 Nutrition; 3.1.1 Fats; 3.1.2 Protein; 3.1.3 Carbohydrates; 3.1.4 Vitamins and; 3.1.5 Mother's milk -- the only true superfood; 3.2 Role of Lifestyle; References; Chapter Four 4.1 Introduction4.2 Epigenetic gene regulation; 4.3 Global climate change; References; Appendix; A1 Introduction; A2 The Nervous System; A2.1 Introduction; A2.2 Cells in the nervous system; A2.3 Regions of the brain; A2.4 Neurotransmitters, neurohormones and neuromodulators; A2.5 Small molecule neuroactive NO and CO; A3 The Endocrine System; A4 The Immune System; References; Abbreviations and Acronyms Used; Index This second book in a two-volume set tells how the healthcare community is working with patients and their caregivers to help improve health using P4 medicine, proper nutrition and a healthy lifestyle. The healthcare community is finding ways to predict one's susceptibility to diseases, so they can be prevented from occurring, when possible. When diseases do emerge, it is developing personalized therapies and ways for patients to participate in their own healthcare. At the same time, systems thinking dispels many misconceptions, such as 'natural' foods and 'superfoods'. In fact, the only true. Drug development. http://id.loc.gov/authorities/subjects/sh97007921 Pharmaceutical chemistry. http://id.loc.gov/authorities/subjects/sh85023026 Integrative medicine. http://id.loc.gov/authorities/subjects/sh2003001256 Human biology. http://id.loc.gov/authorities/subjects/sh85062843 Chemistry, Pharmaceutical https://id.nlm.nih.gov/mesh/D002626 Médicaments Développement. Chimie pharmaceutique. Médecine intégrative. Biologie humaine. MEDICAL Pharmacology. bisacsh Drug development fast Human biology fast Integrative medicine fast Pharmaceutical chemistry fast has work: Volume 2 Systems thinking in medicine and new drug discovery [...] (Text) https://id.oclc.org/worldcat/entity/E39PCH4pMpM4bBV9fDtcf9Yr7b https://id.oclc.org/worldcat/ontology/hasWork FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1993859 Volltext |
| spellingShingle | Smith, Robert E., 1951- Systems thinking in medicine and new drug discovery. Intro; Contents; Preface; Chapter One; 1.1 P4 medicine: predictive, preventive, personalized and participatory; 1.2 Systems primary care medicine; 1.3 Causality in P4SM; 1.4 Explanation, prediction and control in P4 me; 1.5 What P4 medicine does; 1.6 Examples of P4 medicine; 1.7 Important collaborations in P4 medicine; 1.8 P4 and evidence based medicine; 1.9 The Advancing Regulatory Science Initiative; 1.10 The voices of the people; 1.11 Limitations of P4 medicine; 1.12 Metabolomics; 1.12.1 Introduction; 1.12.2 Comparison of LC-MS and GC-MS; 1.12.3 NMR in metabolomics 1.12.4 Receiver operator characteristic (ROC) curves1.12.5 Acute kidney injury (AKI) metabolomics; 1.12.6 Chronic kidney disease (CKD) me; 1.12.7 Metabolomics of acute kidney injury; 1.12.8 Metabolomics of neonatal, pediatric and childhood kidney diseases; 1.12.9 Metabolomics of kidney cancer; 1.12.10 Proteomics; 1.13 Targeted radiation therapy; 1.14 Precision systems medicine that targets cancer stem cel; 1.15 Cancer prevention; 1.16 Systems medicine; References; Chapter Two; 2.1 Previous misconceptions caused by reductionist thinking; 2.2 Chemistry of free radicals and RONS 2.3 How antioxidants really work2.3.1 Poorly liganded iron and the Fenton reaction; 2.3.2 The Nrf2/ARE system; 2.4 The role of the Keap1-Nrf2-ARE signaling system in preventing cardiovascular diseases; 2.5 Role of the Nrf2/ARE antioxidant system in cancer and neurodegenerative diseases; 2.6 Smoldering inflammation; 2.7 The complement system and toll-like receptors in health and disease; References; Chapter Three; 3.1 Nutrition; 3.1.1 Fats; 3.1.2 Protein; 3.1.3 Carbohydrates; 3.1.4 Vitamins and; 3.1.5 Mother's milk -- the only true superfood; 3.2 Role of Lifestyle; References; Chapter Four 4.1 Introduction4.2 Epigenetic gene regulation; 4.3 Global climate change; References; Appendix; A1 Introduction; A2 The Nervous System; A2.1 Introduction; A2.2 Cells in the nervous system; A2.3 Regions of the brain; A2.4 Neurotransmitters, neurohormones and neuromodulators; A2.5 Small molecule neuroactive NO and CO; A3 The Endocrine System; A4 The Immune System; References; Abbreviations and Acronyms Used; Index Drug development. http://id.loc.gov/authorities/subjects/sh97007921 Pharmaceutical chemistry. http://id.loc.gov/authorities/subjects/sh85023026 Integrative medicine. http://id.loc.gov/authorities/subjects/sh2003001256 Human biology. http://id.loc.gov/authorities/subjects/sh85062843 Chemistry, Pharmaceutical https://id.nlm.nih.gov/mesh/D002626 Médicaments Développement. Chimie pharmaceutique. Médecine intégrative. Biologie humaine. MEDICAL Pharmacology. bisacsh Drug development fast Human biology fast Integrative medicine fast Pharmaceutical chemistry fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh97007921 http://id.loc.gov/authorities/subjects/sh85023026 http://id.loc.gov/authorities/subjects/sh2003001256 http://id.loc.gov/authorities/subjects/sh85062843 https://id.nlm.nih.gov/mesh/D002626 |
| title | Systems thinking in medicine and new drug discovery. |
| title_auth | Systems thinking in medicine and new drug discovery. |
| title_exact_search | Systems thinking in medicine and new drug discovery. |
| title_full | Systems thinking in medicine and new drug discovery. Volume two / by Robert E. Smith. |
| title_fullStr | Systems thinking in medicine and new drug discovery. Volume two / by Robert E. Smith. |
| title_full_unstemmed | Systems thinking in medicine and new drug discovery. Volume two / by Robert E. Smith. |
| title_short | Systems thinking in medicine and new drug discovery. |
| title_sort | systems thinking in medicine and new drug discovery |
| topic | Drug development. http://id.loc.gov/authorities/subjects/sh97007921 Pharmaceutical chemistry. http://id.loc.gov/authorities/subjects/sh85023026 Integrative medicine. http://id.loc.gov/authorities/subjects/sh2003001256 Human biology. http://id.loc.gov/authorities/subjects/sh85062843 Chemistry, Pharmaceutical https://id.nlm.nih.gov/mesh/D002626 Médicaments Développement. Chimie pharmaceutique. Médecine intégrative. Biologie humaine. MEDICAL Pharmacology. bisacsh Drug development fast Human biology fast Integrative medicine fast Pharmaceutical chemistry fast |
| topic_facet | Drug development. Pharmaceutical chemistry. Integrative medicine. Human biology. Chemistry, Pharmaceutical Médicaments Développement. Chimie pharmaceutique. Médecine intégrative. Biologie humaine. MEDICAL Pharmacology. Drug development Human biology Integrative medicine Pharmaceutical chemistry |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1993859 |
| work_keys_str_mv | AT smithroberte systemsthinkinginmedicineandnewdrugdiscoveryvolumetwo |